SAN DIEGO, CA - (NewMediaWire) - November 12, 2015 - Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, has announced today the formation of a Clinical Advisory Board made up of top key opinion leaders in the fields of in vitro fertilization (IVF) lead by Dr. Fady Sharara to support the US launch of its Androferti® product. The Clinical Advisory Board will work closely with the Innovus Pharma management team in presenting Androferti®'s strong clinical data at academic and industry meetings in preparation of the launch of the product in the US.
The Clinical Advisory Board will be led by Dr. Fady Sharara, one of the top infertility doctors in the US voted one of the Top Doctors in Infertility by the Washington Post magazine, Washingtonian magazine, and Northern Virginia magazine, among others.
"We are very excited to bring the leading members in the fields of in vitro fertilization to our Clinical Advisory Board. We believe that the quality of the members of the Clinical Advisory Board is a great testimony to the benefit of Androferti® product to patients and to its clinical efficacy. These members will be instrumental in promoting the development, marketing and commercialization of our products to meet the growing demand in the global pharmaceutical market for products which foster in vitro fertilization," said Dr. Bassam Damaj, President and Chief Executive Officer.
"I am honored to be working with Innovus Pharma on Androferti® as to my knowledge this is the only product that was successfully studied in five published clinical trials as a whole formulation as opposed to products basing their claim on the Carnitine ingredient," said Dr. Sharara.
Androferti® has been shown in multiple published clinical trials to statistically increase seminal quality (concentration, motility, morphology and vitality) and enhances spermatozoa quality (decreases of vacuoles in the sperm nucleus, decreases DNA fragmentation, decreases the dynamics of sperm DNA fragmentation, and improvement on the inventory of mobile sperms (REM).
The Company believes that Androferti® is the only product clinically proven to increase the Sperm Quality and enhance Spermatozoa Quality as compared to other products where the claims are based on an ingredient used in the products.
Innovus Pharma obtained the exclusive rights to commercialize the Androferti® in the U.S. and Canada from Q Pharma, Spain in January 2015 and is expected to launch the product before the year end.
About Fady I. Sharara, M.D., FACOG
Fady I. Sharara, M.D., FACOG, is a Board Certified Reproductive Endocrinologist/Infertility specialist, and a Board Certified Obstetrician/Gynecologist. He is the recipient of numerous prestigious awards, and has been consistently voted one of the Top Doctors in Infertility by the Washington Post magazine, Washingtonian magazine, and Northern Virginia magazine, among others. Dr. Sharara is a reviewer for Fertility and Sterility, Human Reproduction, the American Journal of Obstetrics and Gynecology, Human Fertility, Journal of Assisted Reproduction and Genetics. He has published more than 70 scientific papers and book chapters dealing with Infertility and Assisted Reproductive Technologies He received his B.S. in Chemistry in 1982, and his M.D. in 1986 from the American University of Beirut. He was on the Dean's honor list during his premedical and medical studies. He then completed his residency in OB/GYN at George Washington University Hospital in Washington, DC, USA, in 1991, followed by a fellowship in Reproductive Endocrinology and Infertility from 1991 to 1994 at the National Institutes of Health in Bethesda, MD. He moved to Chicago where he was an Assistant Professor at the University of Illinois and Michael Reese Fertility Center between 1994 and 1996. He then returned to the University of Maryland where he was Assistant Professor and head of the IVF program from 1996 to 2000. He was promoted to Associate Professor before his departure from the University of Maryland. Dr Sharara then became the founder and Medical Director for the Virginia Center for Reproductive Medicine (VCRM) in Reston, VA, and has been Clinical professor in the OB/GYN department at George Washington University in Washington, DC since 2007.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products Zestra® for female arousal and EjectDelay® for premature ejaculation and has a total of five marketed products in this space, including Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), Zestra Glide®, Vesele® for promoting sexual and cognitive health, Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.
For more information, go to www.innovuspharma.com, www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.sensumplus.com; www.myandroferti.com
Innovus Pharma's Forward-Looking Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the company, including, but not limited to, receiving patent protection for any of its products, receiving approval or to be compliant with the requirements of any relevant regulatory authority relating to Androferti®, to successfully commercialize such products and to achieve its other development, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.